Benralizumab 10 mg vs placebo
Rate of severe exacerbations requiring hospitalisation Eosinophils ≥ 220/μL · patients with chronic obstructive pulmonary disease
Benralizumab 10 mg probably leads to lower rate of severe exacerbations requiring hospitalisation Eosinophils ≥… compared with placebo (moderate certainty).
1 finding from 1 review
- Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes onlyRate ratio 0.68 [0.49, 0.94]1 study · 765 participantsModerate